1579 related articles for article (PubMed ID: 12853587)
1. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
2. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
Schulman S; Granqvist S; Holmström M; Carlsson A; Lindmarker P; Nicol P; Eklund SG; Nordlander S; Lärfars G; Leijd B; Linder O; Loogna E
N Engl J Med; 1997 Feb; 336(6):393-8. PubMed ID: 9010144
[TBL] [Abstract][Full Text] [Related]
3. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
[TBL] [Abstract][Full Text] [Related]
4. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
Kearon C; Gent M; Hirsh J; Weitz J; Kovacs MJ; Anderson DR; Turpie AG; Green D; Ginsberg JS; Wells P; MacKinnon B; Julian JA
N Engl J Med; 1999 Mar; 340(12):901-7. PubMed ID: 10089183
[TBL] [Abstract][Full Text] [Related]
5. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
Ridker PM; Goldhaber SZ; Danielson E; Rosenberg Y; Eby CS; Deitcher SR; Cushman M; Moll S; Kessler CM; Elliott CG; Paulson R; Wong T; Bauer KA; Schwartz BA; Miletich JP; Bounameaux H; Glynn RJ;
N Engl J Med; 2003 Apr; 348(15):1425-34. PubMed ID: 12601075
[TBL] [Abstract][Full Text] [Related]
6. Dalteparin versus unfractionated heparin in critically ill patients.
; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
Lee AY; Rickles FR; Julian JA; Gent M; Baker RI; Bowden C; Kakkar AK; Prins M; Levine MN
J Clin Oncol; 2005 Apr; 23(10):2123-9. PubMed ID: 15699480
[TBL] [Abstract][Full Text] [Related]
8. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
Agnelli G; Prandoni P; Santamaria MG; Bagatella P; Iorio A; Bazzan M; Moia M; Guazzaloca G; Bertoldi A; Tomasi C; Scannapieco G; Ageno W;
N Engl J Med; 2001 Jul; 345(3):165-9. PubMed ID: 11463010
[TBL] [Abstract][Full Text] [Related]
9. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.
Breddin HK; Hach-Wunderle V; Nakov R; Kakkar VV;
N Engl J Med; 2001 Mar; 344(9):626-31. PubMed ID: 11228276
[TBL] [Abstract][Full Text] [Related]
10. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
Schulman S; Wåhlander K; Lundström T; Clason SB; Eriksson H;
N Engl J Med; 2003 Oct; 349(18):1713-21. PubMed ID: 14585939
[TBL] [Abstract][Full Text] [Related]
11. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group.
Decousus H; Leizorovicz A; Parent F; Page Y; Tardy B; Girard P; Laporte S; Faivre R; Charbonnier B; Barral FG; Huet Y; Simonneau G
N Engl J Med; 1998 Feb; 338(7):409-15. PubMed ID: 9459643
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Couturaud F; Julian JA; Kearon C
Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
Bick RL
J Support Oncol; 2006 Mar; 4(3):115-20. PubMed ID: 16553136
[TBL] [Abstract][Full Text] [Related]
14. Outpatient treatment of pulmonary embolism with dalteparin.
Kovacs MJ; Anderson D; Morrow B; Gray L; Touchie D; Wells PS
Thromb Haemost; 2000 Feb; 83(2):209-11. PubMed ID: 10739374
[TBL] [Abstract][Full Text] [Related]
15. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
Levine M; Gent M; Hirsh J; Leclerc J; Anderson D; Weitz J; Ginsberg J; Turpie AG; Demers C; Kovacs M
N Engl J Med; 1996 Mar; 334(11):677-81. PubMed ID: 8594425
[TBL] [Abstract][Full Text] [Related]
16. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
Koopman MM; Prandoni P; Piovella F; Ockelford PA; Brandjes DP; van der Meer J; Gallus AS; Simonneau G; Chesterman CH; Prins MH
N Engl J Med; 1996 Mar; 334(11):682-7. PubMed ID: 8594426
[TBL] [Abstract][Full Text] [Related]
17. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
18. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
Monreal M; Lafoz E; Olive A; del Rio L; Vedia C
Thromb Haemost; 1994 Jan; 71(1):7-11. PubMed ID: 8165649
[TBL] [Abstract][Full Text] [Related]
19. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
Turpie AG; Gallus AS; Hoek JA;
N Engl J Med; 2001 Mar; 344(9):619-25. PubMed ID: 11228275
[TBL] [Abstract][Full Text] [Related]
20. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
Samama MM; Cohen AT; Darmon JY; Desjardins L; Eldor A; Janbon C; Leizorovicz A; Nguyen H; Olsson CG; Turpie AG; Weisslinger N
N Engl J Med; 1999 Sep; 341(11):793-800. PubMed ID: 10477777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
